CervoMed Investor Relations Material

CervoMed Inc. is a biotechnology company specializing in the development and commercialization of treatments for age-related neurologic disorders. The company’s key focus is on addressing synaptic dysfunction, a critical factor in neurodegenerative diseases. Its lead product candidate, neflamapimod, is an orally administered small molecule designed to treat conditions such as dementia with Lewy bodies, Alzheimer's disease, and frontotemporal dementia by reversing synaptic dysfunction. CervoMed also has additional programs targeting central nervous system disorders in earlier stages of development. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.